To better identify the mitochondrial changes induced by regorafenib that allow BCL-xL antagonism to synergistically induce cytotoxicity in hepatoma cells, we analyzed the protein levels of BCL-2 members with recognized importance in cell survival. This evidence concerns the gene BCL2 and hepatocellular carcinoma.